Back to Newsroom
Back to Newsroom

Dentsply Sirona, Inc. (XRAY), The Goldman Sachs Group, Inc. (GS) & Allergan plc (AGN): Bronstein, Gewirtz & Grossman, LLC Class Action Update

Friday, 15 February 2019 09:55 AM

Bronstein, Gewirtz and Grossman, LLC

Topic:
Lawsuits

NEW YORK, NY / ACCESSWIRE / February 15, 2019 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss, you can request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Dentsply Sirona, Inc. (NASDAQ: XRAY)
Class Period:
February 20, 2014 - August 7, 2018
Lead Plaintiff Deadline: February 19, 2019
For more info: www.bgandg.com/xray

The Complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, specifically relating to its financial performance and its "innovation," "operational improvement efforts," "new products," and "continued investments in sales and marketing." The complaint alleges that: (1) Dentsply was engaged in an anticompetitive scheme among its three primary distributors that suppressed competition and artificially inflated the price of Dentsply's products; and (2) Dentsply engaged in "channel-stuffing" which rendered the Company's reported sales, financial results and guidance materially false and misleading.

The Goldman Sachs Group, Inc. (NYSE: GS)

Class Period: February 28, 2014 - December 17, 2018
Lead Plaintiff Deadline: February 19, 2019
For more info: www.bgandg.com/gs

The Complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements and/or failed to disclose that: (1) Goldman Sachs participated in a fraud and money-laundering scheme in collusion with 1Malaysia Development Bhd., a Malaysian state-owned investment fund; (2) the foregoing conduct, when revealed, would foreseeably subject Goldman Sachs to heightened regulatory investigations and enforcement; and (3) as a result, Goldman Sachs's public statements were materially false and misleading at all relevant times.

Allergan plc (NYSE: AGN)

Class Period: May 9, 2017- December 19, 2018,
Lead Plaintiff Deadline: February 19, 2019
For more info: www.bgandg.com/agn

The Complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements and/or failed to disclose adverse information. Specifically, the complaint alleges that Allergan concealed from investors the fact that the Company's CE Mark for its textured breast implants and tissue expanders was expiring in Europe.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz

212-697-6484 | [email protected]

SOURCE: Bronstein, Gewirtz & Grossman, LLC

Topic:
Lawsuits
Back to newsroom
Back to Newsroom
Share by: